Rachel Nisbet, MD
Pulmonary Disease · Dacula, GANPI 1609051218
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,037 of the $4,572 with a category attached, or 88.3%. 25 manufacturers reported payments, led by GSK at 26.0% of the total. Reporting peaked in 2019 at $1,539 and has fallen 59.8% since, to $619 in 2025. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 209 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Boehringer Ingelheim$454
- Actelion Pharmaceuticals US, Inc.$450
- Insmed, Inc.$376
- Inspire Medical Systems, Inc.$292
- AstraZeneca$288
- plus $2K from 19 others
Across 78 payments — averaging $3559.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$95K
- AstraZeneca$76K
- United Therapeutics Corporation$54K
- Teva Pharmaceuticals USA, Inc.$15K
- Boehringer Ingelheim$11K
- Chiesi USA, Inc.$10K
- plus $16K from 2 others
What the payments were for
- Food & beverage$4,03788%
- Education$53512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 68 | $1,190 |
| Boehringer Ingelheim | 21 | $454 |
| Actelion Pharmaceuticals US, Inc. | 21 | $450 |
| Insmed, Inc. | 10 | $376 |
| Inspire Medical Systems, Inc. | 12 | $292 |
| AstraZeneca | 12 | $288 |
| Sanofi | 8 | $278 |
| Grifols USA, LLC | 11 | $198 |
| United Therapeutics Corporation | 15 | $185 |
| Pulmonx Corporation | 1 | $168 |
| Johnson & Johnson | 1 | $106 |
| Genentech USA, Inc. | 7 | $97 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Advanced Respiratory, Inc | 3 | $72 |
| CSL Behring | 3 | $59 |
| Baxter Healthcare | 2 | $45 |
| Mylan Specialty L.p. | 2 | $34 |
| Electromed, Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Bayer | 2 | $29 |
| Amgen | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| AbbVie | 1 | $19 |
| Merck | 1 | $19 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,572 in reported general payments places this provider in the 50th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 43 | $915,708 |
| Tyvaso DpiTreprostinil | 25 | $608,390 |
| OfevNintedanib Esylate | 38 | $606,147 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 632 | $512,787 |
| OpsumitMacitentan | 37 | $462,212 |
| AdempasRiociguat | 12 | $169,052 |
| Ambrisentan | 38 | $118,573 |
| Dupixent PenDupilumab | 30 | $112,944 |
| Spiriva RespimatTiotropium Bromide | 102 | $79,243 |
| Fasenra PenBenralizumab | 14 | $76,216 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $64,375 |
| AdcircaTadalafil | 17 | $63,439 |
| Dupixent SyringeDupilumab | 17 | $62,581 |
| Breo ElliptaFluticasone/Vilanterol | 131 | $60,748 |
| Tadalafil | 17 | $56,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $450 | $1,377,92080 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $454 | $694,049153 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,190 | $624,425877 claims |
| BayerAdempas | $29 | $169,05212 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $288 | $139,563178 claims |
| United Therapeutics CorporationAdcirca | $185 | $63,43917 claims |
| Johnson & JohnsonXarelto | $106 | $16,01711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Dacula
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
- Hitendra PatelMarietta$104K
- Eric FlenaughAtlanta$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.